

# Efficient mRNA Delivery in difficult-to-transfect cells with jetMESSENGER® Transfection Reagent


Valérie Moreau-Toussaint, Thibaut Benchimol, Jonathan Havard, Fanny Prémartin, Maxime Dumont, Géraldine Guérin-Peyrou, Guillaume Freund, Alengo Nyamay'Antu, Camille Marion, Cindy Croizier, Fabrice Stock, Patrick Erbacher Polyplus-transfection<sup>®</sup>, Vectura, 75 rue Marguerite Perey, 67400 Illkirch, France


## Abstract


Messenger RNA transfection is a new solution for a wide variety of cells that are difficult to transfect with plasmid DNA including adherent (neurons or primary cells) and suspension cells (lymphocytes). This process has many advantages over DNA transfection: high percentage of transfected cells, faster protein expression following transfection, and no risk of insertional mutagenesis in contrast to plasmid transfer. Furthermore, the last generation of modified mRNA reduces the toxicity and immune response usually induced by mRNA entry into the cytosol (1, 2). The transfection is desirable for a number of applications, including cellular reprogramming, genome editing (CRISPR/Cas9) and vaccines. Polyplus-transfection<sup>®</sup> has developed a novel mRNA transfection. This poster will present the results obtained with various cell lines, fragile and primary cells.






















jetMESSENGER<sup>®</sup> is a registered trademark of Polyplus-transfection<sup>®</sup> \_ipofectamine<sup>®</sup> is a registered trademark of Life Technologies™ Corporation. MessengerMax<sup>™</sup> is a trademark of Life Technologies<sup>™</sup> Corporation.

Size of culture	Amount of mRNA	Volume of jetMESSENGER®
96-well	150 ng	0,3 μL
24-well	500 ng	1 μL
6-well	2 µg	4 μL
T-25	4 µg	8 μL
T-75	10 µg	20 µL